Histrelin Implant (Cpp)

Introduction Overview

Generic Name

Histrelin Implant (CPP)

Brand Name

Supprelin LA

Dosage Form

Subcutaneous implant

Drug Class

Gonadotropin releasing hormones; Hormones / antineoplastics

Pharmacokinetics

Absorption:
Supprelin LA contains histrelin acetate, a potent gonadotropin-releasing hormone (GnRH) analog formulated as a subcutaneous implant that provides continuous and steady systemic drug release. The implant is placed under the skin (usually in the upper arm), allowing slow and sustained absorption of histrelin directly into the bloodstream over an extended period, typically for 12 months. This bypasses first-pass metabolism and results in steady-state plasma concentrations, essential for sustained suppression of the hypothalamic-pituitary-gonadal axis. The continuous delivery avoids the pulsatile exposure that occurs physiologically, effectively desensitizing GnRH receptors.

Distribution:
After absorption, histrelin distributes throughout the systemic circulation. As a peptide, it is largely confined to the extracellular fluid and shows limited distribution into fatty tissues. The volume of distribution is relatively low, consistent with its peptide nature. Histrelin binds sparsely to plasma proteins, which facilitates rapid receptor interaction. Due to its delivery via implant, plasma concentrations remain relatively constant without the peaks and troughs characteristic of injectable dosage forms. The drug's distribution is sufficient to reach target sites in the pituitary gland to exert its pharmacological effect.

Metabolism:
Histrelin is metabolized primarily via proteolytic degradation by peptidases into smaller, inactive peptides and amino acids. Unlike small molecule drugs, histrelin is not extensively metabolized by hepatic cytochrome P450 enzymes. Its metabolism is largely peripheral and not dependent on liver enzyme activity, reducing the risk of metabolic drug interactions. The continuous release from the implant maintains therapeutic drug concentrations despite metabolism. This metabolic pathway ensures minimal systemic accumulation beyond the designed exposure.

Elimination:
The elimination of histrelin involves proteolytic metabolism followed by renal excretion of the resultant small peptides and amino acids. Due to its peptide nature, the parent compound is not excreted unchanged in urine. The implant remains in place for a year providing a prolonged pharmacokinetic profile, after which the implant is removed, terminating drug delivery. The elimination half-life of histrelin is not typically described in standard pharmacokinetic terms because of the continuous-release implant system, but systemic effects persist throughout the implant duration. Renal function may potentially influence clearance of metabolites, but no dosage adjustments are typically necessary.

Dosage Forms

Available Dosage Forms:
Supprelin LA is available as a subcutaneous implant containing 50 mg of histrelin acetate designed for sustained release over 12 months. The implant is a small, flexible rod approximately 4 cm in length, intended for placement under the skin of the upper inner arm by a healthcare professional. There are no oral, injectable, or other topical formulations of Supprelin LA for pediatric use.

Dosages for Adults and Adolescents:
Supprelin LA is primarily indicated for pediatric use to treat central precocious puberty; thus, adult dosing information is limited and typically not applicable. The implant releases histrelin continuously to provide therapeutic plasma concentrations adequate to suppress gonadotropin secretion for up to one year, avoiding the need for monthly injections. For adult patients, particularly those with conditions such as prostate cancer, alternative GnRH analog formulations are used.

Specific Patient Populations:
Supprelin LA is contraindicated for children younger than 2 years of age. The implant is intended for use in children experiencing central precocious puberty to delay premature sexual maturation. Use in pregnant or breastfeeding females is contraindicated or not recommended due to potential harm to the fetus or infant. The implant dosage is standardized and not typically adjusted for weight or renal/hepatic impairment because the depot release provides sustained exposure. Removal of the implant should be performed promptly at the end of the treatment duration. Close monitoring is required to assess clinical response and growth parameters in pediatric patients.

Mechanism Of Action

Supprelin LA delivers histrelin acetate, a synthetic analog of the naturally occurring gonadotropin-releasing hormone (GnRH) produced by the hypothalamus, in a continuous fashion via a subcutaneous implant. Normally, GnRH is secreted in a pulsatile manner, stimulating the anterior pituitary gland to produce and release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn regulate gonadal steroidogenesis and gametogenesis. Histrelin mimics GnRH but with modifications that increase its receptor affinity and biological potency.

When administered continuously rather than in pulses, histrelin causes persistent stimulation of GnRH receptors on pituitary gonadotrophs leading to receptor desensitization and downregulation. This results in a marked decrease in LH and FSH secretion, effectively suppressing the hypothalamic-pituitary-gonadal (HPG) axis. This suppression reduces gonadal sex steroid production (e.g., testosterone in males and estradiol in females), thereby arresting the progression of puberty and alleviating symptoms associated with precocious puberty.

The biochemical interaction involves histrelin binding to the GnRH receptor, a G protein-coupled receptor expressed in the anterior pituitary. Continuous exposure causes receptor internalization and decreased receptor availability on the cell surface. This desensitization diminishes downstream signaling pathways including phospholipase C activation and intracellular calcium mobilization, central to LH and FSH release. The clinical implication is effective and reversible pharmacologic suppression of premature sexual maturation in children.

Compared to other GnRH agonists such as leuprolide or triptorelin, histrelin provides the advantage of a sustained, long-acting delivery system through the implant, ensuring compliance and steady drug release over a 12-month period without the need for frequent injections. Clinical studies demonstrate that this continuous suppression reliably delays pubertal progression with a favorable safety profile.

Pharmacological Actions

Continuous GnRH receptor agonist activity causing desensitization and downregulation of pituitary GnRH receptors.
Suppression of gonadotropin (LH and FSH) secretion from the anterior pituitary gland.
Reduction of gonadal steroid hormone production (testosterone and estradiol) by inhibiting gonadal stimulation.
Delay of pubertal onset and progression by pharmacologic suppression of the hypothalamic-pituitary-gonadal axis.
Provides sustained hormonal suppression over 12 months via a subcutaneous implant delivery system.
Minimal systemic fluctuations in drug levels ensuring consistent receptor desensitization.
Avoidance of the flare effect commonly seen in GnRH agonist therapy by continuous receptor stimulation.
Improvement of clinical symptoms associated with central precocious puberty in pediatric patients.
Potential modulation of hormone-dependent pathological conditions by reducing sex steroid influence.
Reversible suppression allowing normal pubertal progression after implant removal.
Influences growth parameters indirectly via hormonal regulation.
Low risk of metabolic drug interactions due to peptide nature and non-CYP metabolism.

Therapeutic Or Clinical Uses

Treatment of central precocious puberty (CPP) in children to delay early onset of puberty.
Suppression of premature sexual maturation linked to early activation of the hypothalamic-pituitary-gonadal axis.
Management of pediatric patients with idiopathic or organic causes of precocious puberty.
Used in cases where delaying pubertal progression can benefit physical growth and psychosocial development.
Adjunctive hormonal therapy in pediatric endocrine disorders involving premature puberty.
Provision of consistent and durable suppression through a single yearly implant placement.
Alternative to frequent injectable GnRH analogs enhancing compliance and convenience.
Potential off-label use in other hormone-dependent pediatric conditions under specialist guidance.
Control of sex hormone levels in pediatric patients with congenital adrenal hyperplasia or other disorders involving sex steroids.
Clinical utility in helping optimize adult height by delaying premature epiphyseal closure.
Enabling longitudinal monitoring of puberty progression and treatment response through stable drug delivery.

Side Or Adverse Effects

Local irritation, pain, or swelling at the implant site.
Rare extrusion or displacement of the subcutaneous implant requiring medical attention.
Transient initial pubertal symptoms such as vaginal bleeding, breast enlargement, or increase in pubic hair during the first month of therapy.
Body odor changes related to hormonal adjustments in the early treatment phase.
Potential mood and behavioral changes in pediatric patients including irritability, aggression, depression, or emotional lability.
Possible allergic reactions including rash, itching, hives, or swelling of the face or throat.
Uncommon seizure occurrences reported in some treated children.
Headache and fatigue during early treatment periods.
Injection site infections or abscess formation though rare.
Impact on normal growth velocity necessitating regular monitoring of growth parameters.
Gastrointestinal disturbances such as nausea or abdominal pain occasionally reported.
Hormonal withdrawal symptoms following implant removal or at therapy conclusion.
Long-term safety profile generally favorable with continuous post-marketing surveillance.
Potential effects on bone mineral density requiring assessment during prolonged therapy.
Laboratory abnormalities including changes in sex hormone levels and gonadotropin suppression.

Precautions

Inform healthcare providers about use of Supprelin LA prior to any surgical or diagnostic procedure.
Avoid use in children younger than 2 years of age.
Monitor growth and development regularly to assess treatment efficacy and adverse effects.
Patients with known allergy to histrelin or implant components should not receive this therapy.
Caution should be exercised if implant extrusion or infection occurs; surgical removal may be necessary.
Because it may affect certain laboratory tests, inform lab personnel about treatment prior to testing.
Avoid exposure of the implant site to water for 24 hours post-insertion to reduce infection risk.
Advise patients and caregivers to report mood or behavioral changes promptly to manage psychiatric symptoms.
Refrain from heavy physical activity involving the arm receiving the implant for 7 days post-placement.
Pregnancy is a contraindication; ensure female patients of reproductive age are not pregnant before initiation.
Use with caution in patients with seizure disorders and monitor for neurological symptoms.
Consider potential interaction with other hormone-modulating agents; consult healthcare providers before adding new therapies.
Advise caregivers that implant removal is required after 12 months; delay may prolong suppression unnecessarily.
Patients should not share their implant or medical information with others to prevent misuse.
Close monitoring for signs of allergic reactions or hypersensitivity is warranted.

Warnings

Risk of serious allergic reactions including anaphylaxis; seek immediate medical care for signs of rash, swelling, or breathing difficulties.
Potential for implant extrusion requiring prompt surgical consultation.
Mood and behavioral changes including aggression, irritability, depression, and emotional instability reported; monitor closely and intervene as needed.
Avoid use in pregnancy due to potential fetal harm.
Seizure risk although rare; discontinue if seizures occur.
Do not administer to children under age 2 due to lack of safety and efficacy data.
Potential impact on growth rate necessitates ongoing assessment and endocrinologist follow-up.
Failure to remove implant at recommended time may result in excessive hormone suppression.
Inform patients about possible temporary initial pubertal symptoms that may worsen transiently before improving.
Beware of drug interference with laboratory tests affecting hormone assays and other measurements.
Use caution in patients with pre-existing psychiatric conditions; monitor for exacerbations.
Avoid exposing the implant site to trauma or pressure that could dislodge the device.
Implant site infections, while uncommon, require close observation and treatment.
Patients should report any new or unusual symptoms promptly to healthcare providers.
Inadvertent overdose due to multiple implants or failure to remove should be guarded against.

Contraindication

Known hypersensitivity or allergy to histrelin or any component of the implant.
Children younger than 2 years of age.
Pregnancy or suspected pregnancy due to risk of fetal harm.
Breastfeeding patients unless benefits outweigh risks and under physician supervision.
Patients with pituitary or hypothalamic tumors if not evaluated or under hormonal therapy management.
Infections at the implant insertion site precluding safe placement.
Patients with active severe allergic reactions or anaphylaxis to other GnRH analogs.
Known seizure disorders uncontrolled by therapy may contraindicate use.
Any condition where hormonal suppression would be deleterious or contraindicated.
Concurrent use with other hormone therapies that contraindicate combined administration.
Presence of coagulopathies or bleeding disorders that increase surgical risk during implant insertion.
Known malignancy of the hormone-dependent endocrine organs without appropriate oncologic management.
Unstable psychiatric illness that might be exacerbated by hormonal changes.
Severe renal or hepatic impairment if patient is unable to tolerate peptide breakdown/metabolism.
Patient non-compliance or inability to follow-up for implant removal and monitoring.

Drug Interactions

Co-administration with other hormone-modulating therapies may alter efficacy or increase adverse effects.
Concurrent use of androgenic or estrogenic drugs may counteract the suppressive effects of histrelin.
No significant cytochrome P450-mediated interactions are expected due to peptide metabolism of histrelin.
Potential additive mood or behavioral effects with psychotropic medications; monitor accordingly.
Drugs that affect pituitary function could theoretically influence treatment response but clinical interaction data are limited.
Drug interactions affecting plasma protein binding are unlikely due to low binding of histrelin.
Use with caution in combination with drugs lowering seizure threshold as rare seizures have been reported.
Interactions with immunosuppressants or corticosteroids have not been well studied; monitor carefully.
No known major interactions with over-the-counter vitamins or supplements, but inform healthcare provider.
No known interactions with commonly used pediatric vaccines.
Polypharmacy may increase risk of implant site reactions due to overlapping toxicities.
Potential interference with hormonal assay laboratory tests; advise lab personnel accordingly.
No known interactions affecting implant integrity or release kinetics.
Consult healthcare professionals before initiating or discontinuing any medications during therapy.
Drug interaction profile remains favorable but requires continued vigilance during combined therapies.

Preparations Of The Drug

Supprelin LA implant: subcutaneous rod containing 50 mg histrelin acetate designed for 12-month sustained release.
Sterile, single-use implant device preloaded and ready for insertion under local or minimal sedation.
Accompanying instructions and surgical materials for insertion and removal by qualified healthcare professionals.
Packaging includes implant, surgical strips, and storage container maintaining sterility.
Supplied with patient information leaflet detailing indications, administration, and safety precautions.
Storage requirements generally room temperature away from moisture and light according to prescribing information.
No oral, injectable, or topical formulations of Supprelin LA available for pediatric indications.
Alternative brand with same active ingredient includes Vantas, primarily used for adult prostate cancer.
Packaging configured for single patient use only; implants not designed for reuse or portioning.
Disposal instructions to minimize environmental impact and ensure safe handling of residual device materials.
Available only by prescription and implant insertion performed exclusively by trained healthcare providers.
Implant includes biocompatible materials to minimize tissue reaction and ensure patient safety.
Lot-specific expiration dates and batch numbers ensure traceability and quality control.
Not intended for self-administration; insertion and removal require clinic visit.
Patient support materials and resources are available to assist in therapy adherence and follow-up.